/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?
With a promoter who is unafraid to make bold bets and pivot to businesses holding more promise, investors can only look forward to better times.
